Mizuho Securities analyst Anthony Petrone has maintained their bullish stance on ADMA stock, giving a Buy rating on March 3.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Anthony Petrone has given his Buy rating due to a combination of factors that highlight the potential growth and stability of ADMA Biologics. The recent filing of the 10-K report has alleviated previous accounting concerns, shifting investor focus towards the promising expansion of ASCENIV. Petrone notes that the potential revenue from ASCENIV could reach between $1.6 billion and $1.9 billion, significantly exceeding current levels and indicating a strong growth trajectory.
Furthermore, the company’s strategic plasma supply agreements and the anticipated approval of Ig yield enhancements are expected to bolster production capacity and sales. These enhancements could lead to a substantial increase in revenue, with estimates suggesting an additional $100 million to $300 million annually. The combination of these factors, along with a robust demand for ASCENIV, supports Petrone’s optimistic outlook and Buy rating for ADMA Biologics.
Petrone covers the Healthcare sector, focusing on stocks such as ADMA Biologics, Teleflex, and Lantheus. According to TipRanks, Petrone has an average return of 6.5% and a 47.69% success rate on recommended stocks.
In another report released on March 3, Cantor Fitzgerald also maintained a Buy rating on the stock with a $25.00 price target.